What is REGiMMUNE?
REGiMMUNE is a clinical-stage biotechnology enterprise dedicated to the development of innovative treatments for immune disorders. The company specializes in harnessing the patient's immune system to induce tolerance, a critical mechanism for achieving anti-tumor responses and managing complex autoimmune conditions. By focusing on immune modulation and the precise application of regulatory T cells, REGiMMUNE aims to provide transformative therapeutic options for patients who have historically lacked effective treatment pathways.
Positioned at the intersection of regenerative medicine and immunology, the company operates as a high-authority player in the life sciences market. Its business model centers on the development of proprietary platforms that address the underlying causes of immune dysfunction, rather than merely managing symptoms. This strategic focus has allowed the firm to maintain a competitive edge in the rapidly evolving landscape of personalized medicine.
How much funding has REGiMMUNE raised?
REGiMMUNE has raised a total of $26M across 5 funding rounds:
Angel/Seed
$1.6M
Series A
$4.2M
Series B
$6M
Series C
$5M
Series D
$9.2M
Angel/Seed (2006): $1.6M with participation from Japan Asia Investment
Series A (2007): $4.2M led by Fund Creation, Yasuda Enterprise Development, Orix Capital Corporation, Jafco Ventures, Mitsubishi Corporation, and Japan Asia Investment
Series B (2008): $6M supported by Yasuda Enterprise Development, Friendly Partners, Fund Creation, Japan Asia Investment, and AC Ventures
Series C (2012): $5M featuring Shinkin Capital, DaiwaEnterprise, SMBC Venture Capital, Japan Asia Investment Co., and Medinet Co.
Series D (2014): $9.2M backed by Japan Asia Investment Co., Mizuho Capital, Mitsui Sumitomo Insurance, Nippon Venture Capital, and SMBC Venture Capital Co., Ltd.
Key Investors in REGiMMUNE
Japan Asia Investment Co.
Japan Asia Investment Co., Ltd. is an investment firm that connects Japan and Asia, focusing on sectors including healthcare, energy, and infrastructure to foster innovative ideas.
Yasuda Enterprise Development
Yasuda Enterprise Development Co Ltd is a Tokyo-based firm operating within the venture capital and private equity industry, providing essential growth capital to emerging enterprises.
Fund Creation
Fund Creation offers high-quality financial products and services, focusing on sustainability and providing strategic investment opportunities for businesses and individuals.
What's next for REGiMMUNE?
With the support of its latest capital injection, REGiMMUNE is well-positioned to accelerate its clinical trial programs and expand its research capabilities. The company's strategic roadmap likely involves deepening its partnerships with medical institutions and enhancing its manufacturing processes for cell-based therapies. As it moves toward potential commercialization, the firm will continue to leverage its strong investor base to navigate the regulatory hurdles inherent in the biotech industry.
Future growth will be defined by the company's ability to demonstrate long-term efficacy in its lead candidates. By maintaining its focus on immune modulation, REGiMMUNE is poised to play a pivotal role in the next generation of therapeutic interventions, potentially setting new standards for how immune-related diseases are treated on a global scale.
